Nicole Kidman is speaking up for SeraLabs. The Oscar, Golden Globe and Emmy Award-winning actress was named the brand’s first strategic business partner and global brand ambassador for its topical products. In addition to being the face of the brand, Kidman will play an integral role in the strategic direction of product development and messaging, company officials said.
“We could not be more excited by Nicole’s decision to join our team,” said Nancy Duitch, SeraLabs CEO and CURE Pharmaceutical Chief Strategic Officer. “We wanted to work with someone who genuinely cares about growing the business as much as we do. A person just looking to lend their name was never going to work for us. She is savvy, forward-thinking and embodies our brand values.”
Duitch said that Kidman became a proponent of the benefits of topical CBD when she experimented with it on an ankle injury last summer. She will bring her vast experience of the beauty sector to help SeraLabs boost its multi-channel distribution efforts and sales for its anti-aging skincare line, Seratopical and topical ultra-hydrating and pain relief body creams and serums. The deal includes nine current SeraLabs topical products with an additional three products set to launch in 2021 where Kidman will be key in development.
SeraLabs also produces products for private label, and while Kidman will be working on the branded products, she brings a high-profile face to the company that could boost its overall presence.
“The partnership with SeraLabs was an easy decision for me,” said Kidman. “With my injury last year, I experienced the benefit of CBD wellness products firsthand. I believe these products are a vital solution in health and wellness and Nancy and SeraLabs are a company I believe in. Joining them in this partnership is something I am very excited about.”
SeraLabs was founded in 2018 and is a global leader in the health, wellness, and beauty sectors. CURE Pharmaceutical Holdings which acquired SeraLabs in 2020 is focused on the innovation of pharmaceutical technology, wellness products and drug delivery. “The growth and global interest of our newest acquisition SeraLabs has been tremendous over the past few months,” said Cure Pharmaceutical CEO, Rob Davidson. “Nicole will undoubtedly help SeraLabs reach more consumers than ever before and grow our revenue exponentially over the next few years.”